LianBio (LIANY)

OTCMKTS · Delayed Price · Currency is USD
0.122
0.00 (0.00%)
Apr 29, 2026, 10:34 AM EST
-35.72%
Market Cap 13.20M
Revenue (ttm) n/a
Net Income (ttm) -87.98M
Shares Out 108.17M
EPS (ttm) -0.82
PE Ratio n/a
Forward PE n/a
Dividend 0.38 (311.48%)
Ex-Dividend Date Jul 15, 2025
Volume n/a
Average Volume 103,179
Open 0.122
Previous Close 0.122
Day's Range 0.122 - 0.122
52-Week Range 0.030 - 0.439
Beta 0.10
RSI 46.99
Earnings Date n/a

About LianBio

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of FGFR2 ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2019
Employees 163
Stock Exchange OTCMKTS
Ticker Symbol LIANY
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.